Development and validation of a sensitive, fast and simple LC-MS/MS method for the quantitation of favipiravir in human serum

Basit Öğe Kaydı
dc.contributor.authorOnmaz, Duygu Eryavuz
dc.contributor.authorAbusoglu, Sedat
dc.contributor.authorOnmaz, Mustafa
dc.contributor.authorYerlikaya, Fatma Humeyra
dc.contributor.authorUnlu, Ali
dc.date.accessioned2024-02-23T14:12:34Z
dc.date.available2024-02-23T14:12:34Z
dc.date.issued2021
dc.departmentNEÜen_US
dc.description.abstractFavipiravir is a broad-spectrum inhibitor of viral RNA polymerase. It is currently used as a possible treatment for coronavirus disease 2019 (COVID-19). Pre-clinical or clinical trials of favipiravir require robust, sensitive, and accurate bioanalytical methods for quantitation of favipiravir levels. Recently, several studies have been reported about developing a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for measuring favipiravir levels. However, these methods were validated predominantly for plasma samples, electrospray ionization was operated only in negative or positive mode, and clinical application of these methods has not been applied for patients with COVID-19. This study aimed was to develop a validated LC-MS/MS method for the measurement of favipiravir levels in positive and negative electrospray ionization mode and to perform a pilot study in patients with COVID-19 receiving favipiravir to demonstrate the applicability of this method in biological samples. Simple protein precipitation was used for the extraction of favipiravir from the desired matrix. Favipiravir levels were quantitated using MS / MS with an electrospray ionization source in positive and negative multiple reaction monitoring (MRM) mode. The chromatographic detection was performed on a reverse-phase Phenomenex C18 column (50 mm x 4.6 mm, 5 mu m, 100 angstrom) with gradient elution using 0.1% formic acid in water and 0.1% formic acid in methanol as mobile phase. The method was linear over the concentration ranges of 0.048-50 mu g/mL (in negative ionization mode) and 0.062-50 mu g/mL (in positive ionization mode) with a correlation coefficient (r2) better than 0.998. The total run time was 3.5 min. The intra-assay and inter-assay % CV values were less than 7.2% and 8.0%, respectively. A simple, rapid and robust LC-MS / MS method was developed for the measurement of favipiravir and validation studies were performed. The validated method was successfully applied for drug level measurement in COVID-19 patients receiving favipiravir.en_US
dc.identifier.doi10.1016/j.jchromb.2021.122768
dc.identifier.issn1570-0232
dc.identifier.issn1873-376X
dc.identifier.pmid34052564en_US
dc.identifier.scopus2-s2.0-85106565812en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1016/j.jchromb.2021.122768
dc.identifier.urihttps://hdl.handle.net/20.500.12452/12116
dc.identifier.volume1176en_US
dc.identifier.wosWOS:000656918100013en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofJournal Of Chromatography B-Analytical Technologies In The Biomedical And Life Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectFavipiraviren_US
dc.subjectCovid-19en_US
dc.subjectTandem Mass Spectrometryen_US
dc.subjectValidationen_US
dc.titleDevelopment and validation of a sensitive, fast and simple LC-MS/MS method for the quantitation of favipiravir in human serumen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu